Skip to main content
. 2017 Mar 29;24(4):409–416. doi: 10.1097/GME.0000000000000786

FIG. 3.

FIG. 3

Effect of each of three doses of TX-004HR at 12 weeks compared with placebo on the secondary endpoints of (A) severity of vaginal dryness and (B) severity of vulvar and/or vaginal itching or irritation (MITT population, n = 747). P < 0.05; P < 0.01; P < 0.0001 versus placebo. LS, least square; MITT, modified intent-to-treat.